NYSE:RCUS Arcus Biosciences Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Arcus Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $28.23 +1.73 (+6.53%) (As of 07/5/2022 03:39 PM ET) Add Compare Share Today's Range$25.86▼$28.3050-Day Range$17.23▼$26.5052-Week Range$16.74▼$49.10Volume21,881 shsAverage Volume838,743 shsMarket Capitalization$2.02 billionP/E Ratio51.33Dividend YieldN/APrice Target$60.86 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Arcus Biosciences MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside118.0% Upside$60.86 Price TargetShort InterestBearish15.54% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$291,220 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.03) to ($4.75) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.1.86 out of 5 starsMedical Sector675th out of 1,428 stocksPharmaceutical Preparations Industry332nd out of 680 stocks 3.5 Analyst's Opinion Consensus RatingArcus Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 6 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $60.86, Arcus Biosciences has a forecasted upside of 118.0% from its current price of $27.91.Amount of Analyst CoverageArcus Biosciences has received no research coverage in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.54% of the float of Arcus Biosciences has been sold short.Short Interest Ratio / Days to CoverArcus Biosciences has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Arcus Biosciences has recently decreased by 2.84%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldArcus Biosciences does not currently pay a dividend.Dividend GrowthArcus Biosciences does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RCUS. Previous Next 1.1 News and Social Media Coverage News SentimentArcus Biosciences has a news sentiment score of 0.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.80 average news sentiment score of Medical companies. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Arcus Biosciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $291,220.00 in company stock.Percentage Held by Insiders12.70% of the stock of Arcus Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions73.54% of the stock of Arcus Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Arcus Biosciences are expected to decrease in the coming year, from ($4.03) to ($4.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Arcus Biosciences is 50.75, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 82.25.Price to Earnings Ratio vs. SectorThe P/E ratio of Arcus Biosciences is 50.75, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 74.76.Price to Book Value per Share RatioArcus Biosciences has a P/B Ratio of 2.33. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RCUS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Arcus Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address About Arcus Biosciences (NYSE:RCUS) StockArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company also develops Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combination with Zimberelimab; Quemliclustat, a small-molecule CD73 inhibitor is in a Phase 1/1b study for the treatment of first-line metastatic pancreatic cancer; and AB521, an oral and small molecule HIF-2a inhibitor that is in Phase 1 study for the treatment of patients with von Hippel- Lindau disease. It has a clinical development collaboration agreement with Strata Oncology, Inc. to evaluate Zimberelimab; a collaboration with AstraZeneca, BVF Partners L.P to evaluate domvanalimab, its investigational anti-TIGIT antibody, in combination with Imfinzi (durvalumab) in a registrational Phase 3 clinical trial in patients with unresectable Stage III non-small cell lung cancer; and license agreements with Taiho Pharmaceutical Co., Ltd, Abmuno Therapeutics LLC, and WuXi Biologics to develop anti-CD39 antibody for the treatment of cancer. The company was incorporated in 2015 and is headquartered in Hayward, California.Read More RCUS Stock News HeadlinesJune 27, 2022 | apnews.comPrecision BioSciences Announces Closing of Underwritten Offering of Common StockJune 25, 2022 | finance.yahoo.comArcus Biosciences, Inc.'s (NYSE:RCUS) Stock is Soaring But Financials Seem Inconsistent: Will The Uptrend Continue?June 24, 2022 | nasdaq.comArcus Biosciences Inc Shares Close the Week 20.6% Higher - Weekly WrapJune 23, 2022 | nasdaq.comPrecision BioSciences' (DTIL) Stock Up This Week: Here's WhyJune 23, 2022 | americanbankingnews.comTerry J. Rosen Sells 4,241 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) StockJune 23, 2022 | americanbankingnews.comCarolyn C. Tang Sells 1,400 Shares of Arcus Biosciences, Inc. (NYSE:RCUS) StockJune 23, 2022 | americanbankingnews.comArcus Biosciences, Inc. (NYSE:RCUS) COO Jennifer Jarrett Sells 6,081 SharesJune 22, 2022 | finance.yahoo.comWhy Precision BioSciences Shares Are Surging TodayJune 22, 2022 | bizjournals.comDurham gene editing firm inks billion-dollar deal with NovartisJune 22, 2022 | americanbankingnews.comArcus Biosciences, Inc. (NYSE:RCUS) President Juan C. Jaen Sells 2,333 SharesJune 19, 2022 | americanbankingnews.comArcus Biosciences, Inc. (NYSE:RCUS) Receives $54.33 Consensus Price Target from AnalystsJune 17, 2022 | bizjournals.comCombining to cure: Arcus founders talk strategy and legacyJune 13, 2022 | nasdaq.comArcus Biosciences Inc Shares Close the Day 12.2% Lower - Daily WrapJune 6, 2022 | msn.comArcus Biosciences Earnings Perspective: Return On Capital EmployedMay 31, 2022 | finance.yahoo.comArcus Biosciences to Participate in the Goldman Sachs 43rd Annual Global Healthcare ConferenceMay 18, 2022 | nasdaq.comArcus Biosciences Inc Shares Close the Day 10.1% Lower - Daily WrapMay 13, 2022 | seekingalpha.comArcus medical chief leaves ahead of anti-TIGIT readout - Endpoints NewsMay 12, 2022 | finance.yahoo.comRoche (RHHBY) Phase III NSCLC Study Disappoints, Stock DownMay 11, 2022 | finance.yahoo.comArcus Biosciences (NYSE:RCUS) shareholders have earned a 34% CAGR over the last three yearsMay 11, 2022 | investing.comArcus Biosciences Shares Plunge Over 30% Following Competitor TIGIT Program FailureMay 10, 2022 | nasdaq.comArcus Biosciences Inc Shares Close the Day 11.7% Higher - Daily WrapMay 9, 2022 | investing.comArcus Biosciences Posts Wider-than-Expected Q1 LossMay 9, 2022 | nasdaq.comArcus Biosciences Inc Shares Near 52-Week Low - Market MoverMay 8, 2022 | seekingalpha.comArcus Biosciences Q1 2022 Earnings PreviewApril 27, 2022 | nasdaq.comOversold Conditions For Arcus Biosciences (RCUS)See More Headlines Industry, Sector and Symbol Stock ExchangeNYSE Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNYSE:RCUS CUSIPN/A CIK1724521 Webwww.arcusbio.com Phone(510) 694-6200FaxN/AEmployees366Year FoundedN/ACompany Calendar Last Earnings5/09/2022Today7/05/2022Next Earnings (Estimated)8/04/2022Fiscal Year End12/31/2022Price Target and Rating Average Stock Price Forecast$60.86 High Stock Price Forecast$100.00 Low Stock Price Forecast$42.00 Forecasted Upside/Downside+115.6%Consensus RatingBuy Rating Score (0-4)3 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)$0.55 Trailing P/E Ratio51.33 Forward P/E RatioN/A P/E GrowthN/ANet Income$52.83 million Net Margins14.67% Pretax Margin15.39% Return on Equity8.25% Return on Assets4.71% Debt Debt-to-Equity RatioN/A Current Ratio7.84 Quick Ratio7.84 Sales & Book Value Annual Sales$382.88 million Price / Sales5.29 Cash Flow$0.93 per share Price / Cash Flow30.30 Book Value$11.98 per share Price / Book2.36Miscellaneous Outstanding Shares71,720,000Free Float62,611,000Market Cap$2.02 billion OptionableOptionable Beta0.74 Arcus Biosciences Frequently Asked Questions Should I buy or sell Arcus Biosciences stock right now? 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Arcus Biosciences in the last twelve months. There are currently 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Arcus Biosciences stock. View analyst ratings for Arcus Biosciences or view top-rated stocks. What is Arcus Biosciences' stock price forecast for 2022? 6 brokers have issued 1 year target prices for Arcus Biosciences' shares. Their RCUS stock forecasts range from $42.00 to $100.00. On average, they predict Arcus Biosciences' stock price to reach $60.86 in the next twelve months. This suggests a possible upside of 116.0% from the stock's current price. View analysts' price targets for Arcus Biosciences or view top-rated stocks among Wall Street analysts. How has Arcus Biosciences' stock price performed in 2022? Arcus Biosciences' stock was trading at $40.47 on January 1st, 2022. Since then, RCUS stock has decreased by 30.4% and is now trading at $28.17. View the best growth stocks for 2022 here. When is Arcus Biosciences' next earnings date? Arcus Biosciences is scheduled to release its next quarterly earnings announcement on Thursday, August 4th 2022. View our earnings forecast for Arcus Biosciences. How were Arcus Biosciences' earnings last quarter? Arcus Biosciences, Inc. (NYSE:RCUS) released its earnings results on Monday, May, 9th. The company reported ($0.96) earnings per share for the quarter, missing the consensus estimate of $0.83 by $1.79. The business had revenue of $18.01 million for the quarter, compared to the consensus estimate of $163.47 million. Arcus Biosciences had a net margin of 14.67% and a trailing twelve-month return on equity of 8.25%. During the same quarter in the previous year, the business earned ($1.08) EPS. View Arcus Biosciences' earnings history. Who are Arcus Biosciences' key executives? Arcus Biosciences' management team includes the following people: Dr. Terry J. Rosen Ph.D., Co-Founder, Chairman & CEO (Age 62, Pay $932.12k)Dr. Juan Carlos Jaen Ph.D., Co-Founder, Pres & Director (Age 64, Pay $838.2k)Mr. Robert C. Goeltz II, Principal Financial & Accounting Officer and CFO (Age 49, Pay $613.2k) (LinkedIn Profile)Ms. Jennifer A. Jarrett M.B.A., COO & Director (Age 51, Pay $828.2k) (LinkedIn Profile)Ms. Carolyn C. Tang J.D., Gen. Counsel & Corp. Sec. (Age 43, Pay $603.2k) (LinkedIn Profile)Dr. Stephen Young Ph.D., Sr. VP of Technology & Quantitative Biology (Age 53)Dr. Jonathan Yingling Ph.D., Chief Scientific Officer (Age 53)Ms. Katherine Bock, VP of Investor Relations & Corp. StrategyHolli Kolkey, VP of Corp. CommunicationsMs. Yvonne Gehring, Sr. VP of HR & Operations What is Terry Rosen, Ph.D.'s approval rating as Arcus Biosciences' CEO? 4 employees have rated Arcus Biosciences CEO Terry Rosen, Ph.D. on Glassdoor.com. Terry Rosen, Ph.D. has an approval rating of 100% among Arcus Biosciences' employees. This puts Terry Rosen, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. Who are some of Arcus Biosciences' key competitors? Some companies that are related to Arcus Biosciences include Grifols (GRFS), Maravai LifeSciences (MRVI), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), Intra-Cellular Therapies (ITCI), Alkermes (ALKS), Apellis Pharmaceuticals (APLS), Hypera (HYPMY), Ultragenyx Pharmaceutical (RARE), Cerevel Therapeutics (CERE), Evotec (EVTCY), Arrowhead Pharmaceuticals (ARWR) and Zai Lab (ZLAB). View all of RCUS's competitors. What other stocks do shareholders of Arcus Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Arcus Biosciences investors own include Horizon Therapeutics Public (HZNP), BioDelivery Sciences International (BDSI), Pfizer (PFE), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), CRISPR Therapeutics (CRSP), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Agile Therapeutics (AGRX) and Advanced Micro Devices (AMD). When did Arcus Biosciences IPO? (RCUS) raised $99 million in an initial public offering on Thursday, March 15th 2018. The company issued 7,100,000 shares at a price of $13.00-$15.00 per share. Citigroup, Goldman Sachs and Leerink Partners served as the underwriters for the IPO. What is Arcus Biosciences' stock symbol? Arcus Biosciences trades on the New York Stock Exchange (NYSE) under the ticker symbol "RCUS." How do I buy shares of Arcus Biosciences? Shares of RCUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Arcus Biosciences' stock price today? One share of RCUS stock can currently be purchased for approximately $28.17. How much money does Arcus Biosciences make? Arcus Biosciences (NYSE:RCUS) has a market capitalization of $2.02 billion and generates $382.88 million in revenue each year. The company earns $52.83 million in net income (profit) each year or $0.55 on an earnings per share basis. How many employees does Arcus Biosciences have? Arcus Biosciences employs 366 workers across the globe. How can I contact Arcus Biosciences? Arcus Biosciences' mailing address is 3928 Point Eden Way, Hayward CA, 94545. The official website for Arcus Biosciences is www.arcusbio.com. The company can be reached via phone at (510) 694-6200 or via email at investorinfo@arcusbio.com. This page (NYSE:RCUS) was last updated on 7/5/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
